Lyvgen Biopharma Completes Series C Funding Led by IDG Capital
February 23, 2021 - Lyvgen Biopharma, a biotech company focused on developing innovative immuno-oncology therapeutics, announces that it has completed Series C founding. This round of financing was led by IDG Capital and included Shanghai FTZ Fund, Suzhou Longmen Venture Capital, CHENGWEI Capital and others, with China Renaissance Group as the exclusive financial adviser.
January 26, 2021
Lyvgen Biopharma (Suzhou) officially opened in BioBAY, Suzhou, China.
Lyvgen Biopharma (Suzhou) officially opened in BioBAY on June 10, 2020. Founded by Dr. Jieyi Wang in 2016, Lyvgen focuses on the development of novel immune-oncology (IO) agonist antibodies. At present, the company has built an CMC center of 2,000 square meters of therapeutic antibodies in BioBAY, Suzhou, China. The company headquarters, R&D center and GMP production site are also under active preparation. Follow us on Linkedlin.
June 10, 2020
Inquiries
General --------------------- Business Development
info@lyvgen.com11111 bd@lyvgen.com
Employment 111111111Clinical
careers@lyvgen.com 1 1clinical@lyvgen.com
+86 021-50663350 phone
+86 021-50663370 fax
Shanghai__------------------__
Suite 601B, Building 8, 1043 Ha Lei Road ----_------
Suzhou
Suite 137, Building C36, 188 Dongping Street
Copyright © 2020 LYVGEN BIOPHARMA. All RightsReserved.